Lucida Medical announced today that it received CE mark approval for its machine learning-based prostate cancer detection software.
Cambridge, UK-based Lucida’s Prostate Intelligence (Pi) software offers a way for radiologists to assess and report MRI imaging studies and support the decision of whether or not to perform a biopsy, while also accurately targeting biopsies where needed, according to a news release.
The company touts Pi as capable of offering rapid “one-stop-shop” diagnoses that enable patients to get an MRI, report and biopsy in one visit while ensuring consistent reporting quality across the imaging networks.
Lucida’s technology uses radiogenomics, machine learning and image processing to analyze the MRI scans. The company touted results presented at the March 2021 European Congress of Radiology indicating that Pi can help automate labor-intensive tasks like marking out lesions while avoiding unnecessary invasive bi…